Fusogenix, a proprietary proto-lipid vehicle (PLV) for genetic medicines, enables the formulation of effective DNA vaccines that can be administered like the flu vaccine. Fusogenix is an effective delivery of DNA payload as it directly drives into cells for potent immune response. Meet the CEO of Entos Pharmaceuticals, Dr. John Lewis. His biotechnology company develops next generation nucleic acid medicines and they just announced their development of a Fusogenix DNA vaccine to prevent COVID-19 infections.
Learn more: https://www.entospharma.com/